Jan H von der Thusen
Overview
Explore the profile of Jan H von der Thusen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ernst S, Aldea M, von der Thusen J, de Langen A, Smit E, Paats M, et al.
Nat Rev Clin Oncol
. 2025 Mar;
PMID: 40087401
Advances in targeted therapies for patients with non-small-cell lung cancer have substantially improved the outcomes of those with actionable alterations in certain oncogenic driver genes. However, acquired resistance to these...
2.
Thunnissen E, Blaauwgeers H, Filipello F, Lissenberg-Witte B, Minami Y, Noguchi M, et al.
Lung Cancer
. 2025 Jan;
199:108060.
PMID: 39793325
Objectives: Evaluating invasion in non-mucinous adenocarcinoma (NMA) of the lung is crucial for accurate pT-staging. This study compares the World Health Organization (WHO) with a recently modified NMA classification. Materials...
3.
Moonen L, Derks J, den Bakker M, Hillen L, van Suylen R, von der Thusen J, et al.
Mod Pathol
. 2024 Dec;
38(3):100677.
PMID: 39631518
Although most patients with pulmonary carcinoid (PC) can be cured by surgery, relapse may occur until 15 years after resection in up to 10% of patients. This is unpredictable at...
4.
Leunissen D, Moonen L, von der Thusen J, den Bakker M, Hillen L, van Weert T, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581377
Introduction: Multi-omic studies have identified three molecular separated pulmonary carcinoid (PC) subgroups (A1, A2, B) with distinctive mRNA expression profiles (e.g., orthopedia homeobox protein [OTP], achaete-scute homolog [ASCL1], and hepatocyte...
5.
Lopuhaa B, von der Thusen J
Histopathology
. 2024 Oct;
86(3):479-480.
PMID: 39428724
No abstract available.
6.
van Huizen L, Blokker M, Daniels J, Radonic T, von der Thusen J, Veta M, et al.
Mod Pathol
. 2024 Oct;
38(1):100633.
PMID: 39424227
Lung cancer is one of the most prevalent and lethal cancers. To improve health outcomes while reducing health care burden, it becomes crucial to move toward early detection and cost-effective...
7.
van Stigt A, von der Thusen J, Mustafa D, van den Bosch T, Lila K, Vadgama D, et al.
J Clin Immunol
. 2024 Oct;
45(1):22.
PMID: 39373788
Granulomatous disease affects up to 20% of patients with Common Variable Immunodeficiency (CVID). Granulomas are comprised of highly activated immune cells, and emerge in response to antigenic triggers. In CVID...
8.
Ernst S, von der Thusen J, Dubbink H, Dingemans A
J Thorac Oncol
. 2024 Sep;
19(9):e44-e45.
PMID: 39242150
No abstract available.
9.
Ernst S, von der Thusen J, Dubbink H, Dingemans A
J Thorac Oncol
. 2024 Aug;
19(8):e29-e30.
PMID: 39112013
No abstract available.
10.
Akram F, de Bruyn D, van den Bosch Q, Trandafir T, van den Bosch T, Verdijk R, et al.
Histopathology
. 2024 Jul;
85(6):909-919.
PMID: 38952117
Aims: Uveal melanoma has a high propensity to metastasize. Prognosis is associated with specific driver mutations and copy number variations, and these can only be obtained after genetic testing. In...